MAR 12, 2015 1:10 PM PDT

Scientists Sequence Genome of Classical Hodgkin Lymphoma

WRITTEN BY: Ilene Schneider
A team of researchers has sequenced the genome of classical Hodgkin lymphoma, illuminating exactly which proteins are altered in individual patients. The findings could pave the way to delivering personalized treatments and more effective options, since current treatments can be toxic and don't work for nearly 20 percent of patients diagnosed with the disease.

In the study, published Dec. 8 and as a plenary paper in the Feb. 12 issue of Blood, researchers sequenced the genomes of 10 different patients, creating a catalog of mutations in the harmful Reed-Sternberg cells that characterize classical Hodgkin lymphoma (cHL). Armed with this information, scientists can develop drugs that target these specific alterations to compensate for what has gone awry.

"Now we have a better idea of what mutations there are, and going forward therapies can be adapted to specific patient populations according to their genomic composition," said senior author Dr. Ethel Cesarman, professor of pathology and laboratory medicine at Weill Cornell Medical College.

Although scientists have sequenced the genomes of many other diseases, the cHL genome has remained elusive due to the difficulty of isolating Reed-Sternberg cells, which usually comprise less than 1 percent of a total cHL tumor. The team employed a technique that separates larger cells and looks at the proteins on their surface, called fluorescence-activated cell sorting, to isolate the Reed-Sternberg cells and sequence the cancer genome, said senior author Dr. Mikhail Roshal, a pathologist at Memorial Sloan Kettering Cancer Center.

Once the researchers could see the genes of the cancerous cells, they examined the data for trends. About two-thirds of patients had mutations in the protein Beta-2-microglobulin, which make the Reed-Sternberg cells hide from the immune system. Patients with this mutation actually have a fairly positive prognosis, with nearly an 80 percent likelihood of being cured. Though their outcomes may originate in their typically younger ages - the median age of patients with this mutation is 30, compared with 47 for those without it - and tumor subtype, which is less aggressive than other forms of Hodgkin, understanding this common mutation allows scientists to continue improving existing medications, perhaps by reducing the dosage, Cesarman said.

Working with graduate student and first author Jonathan Reichel, Cesarman and Roshal also discovered other mutations in the cells that already have been cataloged, studied or have a corresponding treatment in other cancers. In these cases, doctors can sequence a cHL patient's tumor (which is already common practice for other cancers and now feasible for cHL), identify their altered gene, and provide an effective corresponding treatment.

"Being able to sort and purify these cells was a breakthrough," Cesarman said. "Knowing the genomics can eventually help to personalize treatment for these patients."

Source: Cornell University
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
FEB 15, 2021
Genetics & Genomics
Green Tea Boosts a DNA-Repairing, Tumor-Suppressing Protein
FEB 15, 2021
Green Tea Boosts a DNA-Repairing, Tumor-Suppressing Protein
Green tea has been lauded for its medicinal qualities, though it's been difficult to show that definitively. A new study ...
MAR 15, 2021
Cell & Molecular Biology
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
MAR 15, 2021
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
Cells are packed full of organelles and molecules like proteins floating in a liquid known as cytoplasm. In recent years ...
APR 13, 2021
Genetics & Genomics
Skull Fossil Yields One of the Oldest Modern Human Genomes
APR 13, 2021
Skull Fossil Yields One of the Oldest Modern Human Genomes
DNA from a very old skull is changing what we know about when and where early humans lived.
APR 14, 2021
Genetics & Genomics
The Smell of Home: Insights Into Scent Imprinting
APR 14, 2021
The Smell of Home: Insights Into Scent Imprinting
Right after birth, young animals go through a period in which they 'imprint,' or fixate on sights and smells that they'r ...
APR 18, 2021
Genetics & Genomics
The Biology of Autism May Depend on Sex
APR 18, 2021
The Biology of Autism May Depend on Sex
It's been unclear whether boys are diagnosed with autism spectrum disorder more often because of detection issues, or if ...
APR 27, 2021
Genetics & Genomics
A Genetic Path Forward For Endangered Sumatran Rhinos
APR 27, 2021
A Genetic Path Forward For Endangered Sumatran Rhinos
There are fewer than 100 Sumatran rhinoceroses remaining in the world, making this animal one of the world's most endang ...
Loading Comments...